Trial Profile
Durvalumab (MEDI4736), Tremelimumab and Palliative Hypofractionated Image Guided Radiation Therapy (HIGRT) in Patients With Recurrent/Metastatic Squamous Cell Carcinomas of the Head and Neck Previously Treated With Immune Checkpoint Inhibitors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 23 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 11 Jan 2022 Planned End Date changed from 13 Nov 2021 to 31 Dec 2022.
- 19 May 2021 Planned End Date changed from 15 Feb 2022 to 13 Nov 2021.